The Sealy Trust is a uOttawa fund created to support translational cancer research. It will generate $200,000/year for 10 years.

A committee chaired by Dr. Ian Lorimer will receive, evaluate and recommend to the Dean funding of proposals that foster translational cancer research in line with the terms of reference of the Sealy Trust (see attached Terms of Reference).

This competition is open to uOttawa faculty.

The purpose of the fund is to enhance the translation of discovery into improved clinical management of cancer patients.

Applications may take the form of requests for salary support for professional personnel (particularly clinician/scientists), pilot projects, infrastructure that supports multiple investigators, or any other worthy expenditure that might augment the quality or quantity of translational cancer research at uOttawa.

Multi-year funding will be considered but continuation of support beyond a first year will be contingent on receipt and approval of annual reports.

Opportunities for leverage of funds from the Sealy Trust will be viewed very positively as will proposals that increase the productive interactions between laboratory- and clinical-based investigators.

Successful applicants will receive the funds in new cost centers/research accounts and expenditures will conform to normal uOttawa practices.

Applications should be submitted electronically on the form attached and received by Lynn Crosbie (lcrosbie@ohri.ca) by Tuesday, October 31, 2017 (11:59 p.m.). CVs of each applicant should be attached to the application.
The Joan Sealy Trust for Cancer Research

Terms of Reference

The Joan Sealy Chair for Lung Cancer Research at the University of Ottawa (University) was initially established with a generous contribution of $1,000,000 from the Sealy Family to the Ottawa Regional Cancer Foundation (ORCF) in 2003. The University matched this donation to create a $2 million endowment fund that was used to generate interest to support the Chair from 2003 until 2011.

In light of the current low rate of interest being earned on investments, the parties who created the endowment fund agree to decapitalize this endowment over a ten (10) year period and, thereby, create the Joan Sealy Trust for Cancer Research (Trust), a direct spent fund.

The Trust will play a pivotal role in spearheading Cancer Research in the Ottawa Hospital Research Institute (OHRI). Particular attention will be paid to early diagnosis, improved treatment and prevention. It is expected that the Trust will facilitate research covering the spectrum of academic activities of the Ottawa Hospital Cancer Program (TOH Cancer Program) while also promoting greater interactions across the University’s Faculty of Medicine.

Barbara Joan Sealy passed away from cancer on May 21, 2002. To her family, Joan’s name was always synonymous with achievement. The family’s intentions for the Joan Sealy Trust is to support Cancer Research, an area that is believed to be ripe for investment, acquiring and translating knowledge into reducing the burden of cancer on our citizens. They feel that the research activities supported by the Trust will foster close associations between the laboratory based- and clinically-based researchers in the OHRI, TOH Cancer Program and the University’s Faculty of Medicine. The Trust will help create unique opportunities to make major advances in the areas of early diagnosis, successful treatment and, ultimately, prevention of cancer.

Purpose of the Trust

The purpose of the Joan Sealy Trust for Cancer Research is to support the needs of the University of Ottawa cancer researchers and to allow this community to avail themselves of opportunities to enhance their contribution towards the mission described above. It is envisaged that some of the funds will be used to attract and/or retain leaders in cancer research to the OHRI and promote greater interactions amongst cancer researchers within the University’s Faculty of Medicine. The Sealy Family wishes to increase awareness, early detection and improve the prevention of cancer by supporting this Trust. It is their wish for the Trust to be used to establish and sustain research efforts focused on understanding or uncovering the underlying causes of cancer with a view to developing and implementing strategies for preventing its occurrence. The Trust will mostly support research in the OHRI Cancer Therapeutics Program facilities, but will also stimulate collaborative projects across the Faculty of Medicine and provide enhanced opportunities.
for practical application of research findings to be exploited through collaborations with the Cancer Program of the Ottawa Hospital.

**Use of Funding**

The University and the ORCF will direct the balance of the Joan Sealy Chair in Lung Cancer Research ($2 million) to the Trust.

The principal and interest income from this $2 million will be made available to the Joan Sealy Trust Allocation Committee to support cancer research in the manner deemed by the committee to be most suited to achieving the goals outlined above. The funding will support research at the OHRI and the University’s basic science departments in a proportion that will best support the research endeavour of both organizations collectively.

**The Joan Sealy Trust Fund Allocation Committee**

The Dean of the Faculty of Medicine, or his/her designate, will establish an Allocation Committee to evaluate proposed uses of the Trust. The Allocation Committee will be chaired by the Director of Research, OHRI Centre for Cancer Therapeutics or his/her designate and will comprise the Vice President of Research, Ottawa Hospital or his/her designate, the Vice- President of Research at the University of Ottawa or his/her designate, the Vice Dean of Research from the Faculty of Medicine, University of Ottawa, and two representatives from the Faculty of Medicine/OHRI with expertise in laboratory or clinical cancer research. Mr. David Sealy or his designate and a representative from the OCRF will be kept informed of the decision-making process and outcomes.